Pfizer’s Statement on Results of Sixth Annual Pay Equity Study Among Colleagues Worldwide

NEW YORK, N.Y., February 25, 2025 – Pfizer Inc. (NYSE:PFE) announced today that, for the sixth consecutive year, an independent compensation expert confirmed equitable pay practices for employees at Pfizer.

The study assessed pay equity for gender worldwide and for minorities in the United States based on compensation data, including base pay and bonuses. The study measured the difference between similar groups of employees when adjusting for factors such as role, grade, job level, and location.

The results indicate that Pfizer compensates female colleagues greater than 99.5% of what male colleagues are paid across the globe. Additionally, in the United States, minorities are paid at parity (100%) with non-minorities. This is the fourth consecutive year that the company has achieved 100% parity with respect to race. Colleagues whose pay is determined by a collective bargaining agreement were not included in the study. Pfizer’s Executive Leadership Team (except the CEO) was included in this analysis.

Pfizer is again releasing median pay gaps for females globally and minorities in the United States. Very few companies release their median pay gaps, and Pfizer is leading the way with this disclosure. Median pay gaps measure the difference between the middle-paid employee from one group against the other and generally reflect representation across organizational levels.

Pfizer’s median pay for females globally is 102.2% of the median pay of males, and the median pay for minorities in the United States is 83.9% of the median pay for non-minorities. We will continue to focus on pay equity in a fair and equitable manner consistent with employment laws.

“We are proud that for six straight years, a compensation expert has confirmed our equitable pay practices at Pfizer. Striving for pay equity across gender and race and disclosing our results year after year is an example of why Pfizer is an amazing workplace. While we have made and maintained progress, we recognize that there is still room for improvement. We remain steadfast in our commitment to building an equitable and inclusive experience for our patients, colleagues, and society at large,” said Payal Sahni Becher, Pfizer’s Chief People Experience Officer, and Executive Vice President.

About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on X at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

DISCLOSURE NOTICE: The information contained in this statement is as of February 25, 2025. Pfizer assumes no obligation to update forward-looking statements contained in this statement as a result of new information or future events or developments.

This statement contains forward-looking information about pay practices at Pfizer that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in business and financial planning, including, without limitation, risks related to Pfizer’s business and prospects, adverse developments in Pfizer’s markets, or developments in the U.S. or global capital markets, credit markets, regulatory environment or economies generally; the impact of COVID-19 on our business, operations and financial results; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results,” as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available
at www.sec.gov and www.pfizer.com.